在童颜针代理权之争陷入"拉锯战"背后，江苏吴中已经退市，爱美客的业绩也难言乐观。 与爱美客争夺"童颜针"代理权的江苏吴中，退市后又有了新动作。 据江苏吴中医药发展股份有限公司（以下简称"江苏吴中"）近日发布的公告，公司拟以8000万元将其持有的全资 孙公司吴中美学生物科技（上海）有限公司（以下简称"上海吴中美学"）100%股权进行对外转让，受让方为上海 青愈生物科技有限公司（以下简称"上海青愈生物"）。 8000万元转让孙公司，退市后江苏吴中"断臂求生" 江苏吴中拟8000万元转让孙公司，主要原因之一便是"还债"。 在公告中，江苏吴中坦言，当前面临现金流短缺压力，且部分存量债务即将到期。转让上海吴中美学100%股权， 可以"优化公司资产结构，盘活存量资产，并切实解决债务问题。" 从标的公司来看，上海吴中美学主要业务为医美产品的研发生产，是江苏吴中医美生科板块旗下的公司。审计报 告显示，截至2025年11月30日，上海吴中美学经审计的资产总额约1.04亿元，所有者权益约7308.92万元。 童颜针代理权之争陷入"拉锯战"，临时措施被取消 此次转让上海吴中美学100%股权，或是江苏吴中收缩医美板块的缩影。 回顾江 ...

Core Viewpoint - The arbitration case regarding the exclusive agency rights for AestheFill products has seen new developments, with REGEN Biotech, Inc. receiving a decision from the Shenzhen International Arbitration Court that revokes previous temporary measures against them, although the case is still under review [2][8]. Group 1: Arbitration Developments - On January 30, 2026, REGEN received a decision from the Shenzhen International Arbitration Court that revoked the temporary measures imposed on September 10, 2025, which restricted REGEN from selling AestheFill products in China and recognized DaTou Company as the exclusive distributor [2][8]. - The temporary measures had been in place since a request from DaTou Company, which claimed exclusive rights to AestheFill products in China [7][8]. - The arbitration case is ongoing, and the recent decision does not represent a final ruling on the matter [8]. Group 2: Company Actions and Responses - DaTou Company was granted exclusive distribution rights for AestheFill products in mainland China through an agreement signed in August 2022 [3]. - In July 2025, REGEN sent a termination notice to DaTou, claiming violations of the agreement and citing reputational damage due to actions by DaTou's parent company, Jiangsu Wuzhong [4][5]. - Jiangsu Wuzhong has publicly defended DaTou's rights, asserting that the exclusive agency agreement remains valid until August 28, 2032 [4]. Group 3: Financial Performance - Jiangsu Wuzhong's stock was delisted on December 31, 2025, due to significant financial irregularities, including inflated revenues and undisclosed related-party transactions [9]. - AestheFill sales accounted for 20.42% of Jiangsu Wuzhong's revenue in 2024, with a significant contribution to its gross profit [10]. - For the first three quarters of 2025, Jiangsu Wuzhong reported a 38.85% decline in revenue, leading to a net loss [10]. Group 4: Market Context - Aimeike, the parent company of REGEN, has experienced declining revenue and net profit, with a 21.49% drop in revenue for the first three quarters of 2025 [11]. - The overall medical aesthetics market in China is facing slower growth, attributed to increased competition and a challenging macroeconomic environment [11].